Hypertension is an expected, on-target effect of VEGF-inhibition which has been reported in up to 80% of patients treated with various inhibitors of the VEGFR signaling pathway [32-35], and which has also been shown to be a biomarker for response in this class of drugs [33,36-38]. This evidence concerns the gene VEGFA and hypertensive disorder.